Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates

This article was originally published in PharmAsia News

Executive Summary

Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.

You may also be interested in...



Infinity In-Licenses Portfolio Of PI3 Kinase Inhibitors For Inflammatory Diseases

Deal is the historically oncology-focused Infinity's first pipeline-building move since it began a strategic alliance with Purdue Pharma and the latter's European affiliate Mundipharma in late 2008.

Intellikine Inc.

Intellikine is developing a group of compounds capable of selectively inhibiting different PI3K isoforms. It can mix and match components to achieve a variety of therapeutic goals. The company's lead program, an mTOR inhibitor for cancer, is nearing the clinic. The start-up also sees significant potential for its PI3 kinase inhibitors in inflammatory diseases and hopes to begin a Phase I trial in that area next year.

FDA Seeks New Generics Chief As Choe Moves On

The US Food and Drug Administration has begun searching for a new director for its Office of Generic Drugs, after announcing that Sally Choe will leave the agency in early October.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC079412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel